Infectious Disease Diagnostics Testing Global Market Report 2024

The infectious disease diagnostics testing market size has grown strongly in recent years. It will grow from $35.09 billion in 2023 to $38.52 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to several factors, including rising disease outbreaks such as SARS, Ebola, and Zika, growing awareness among healthcare professionals and the general public about the importance of early detection and prevention of infectious diseases, an increase in government-funded programs for disease surveillance, control, and prevention, the facilitation of infectious disease spread due to increasing global travel and trade, and increased healthcare spending, particularly in emerging economies.

The infectious disease diagnostics testing market size is expected to see rapid growth in the next few years. It will grow to $58.84 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to several factors, including the continuous emergence of novel pathogens such as new strains of influenza or coronaviruses, the shift towards personalized medicine and targeted therapies, increasing demand for rapid and on-site testing solutions, growing emphasis on epidemiological surveillance and early detection systems, and increased research and development activities focused on developing novel diagnostic technologies and biomarkers. Major trends in the forecast period include the miniaturization and portability of diagnostic devices, adoption of multiplex assays capable of detecting multiple pathogens simultaneously, integration of digital health solutions such as mobile apps and telemedicine platforms, adoption of next-generation sequencing (NGS) technologies in infectious disease diagnostics, advancements in biosensor technologies for rapid and sensitive detection of infectious agents, and integration of AI and machine learning algorithms into diagnostic platforms.

The infectious disease diagnostic testing market is anticipated to experience growth due to an increase in respiratory infections. Respiratory infections affect various parts of the respiratory system and are caused by viral and bacterial transmission through close contact, poor hygiene, crowded living conditions, and seasonal variations. Diagnostic testing for infectious diseases is crucial for accurate identification and treatment of respiratory infections, enabling the precise detection of pathogens such as viruses and bacteria in patient samples. For example, hospitalizations for acute upper respiratory infections saw a 32% increase from 2,114 cases in 2022 to 2,797 cases in 2023, as reported by the Canadian Institute for Health Information.

Leading companies in the infectious disease diagnostic testing market are focusing on innovation, particularly in molecular diagnostics platforms, to remain competitive. These platforms are sophisticated systems designed to detect and analyze nucleic acids from biological samples for diagnostic purposes. Becton Dickinson and Company recently launched the BD COR System, an automated infectious disease molecular diagnostics platform capable of high-throughput processing of up to 1,700 specimens with results delivered within 24 hours. This platform streamlines the molecular laboratory workflow, enhancing efficiency and diagnostic accuracy for diseases such as HPV and STIs.

In August 2022, SSI Diagnostica Group (SSID) acquired TechLab Inc., a US-based developer of infectious disease diagnostic products. This acquisition strengthens SSI Diagnostica Group's position in the infectious disease diagnostics market, aligning with their objectives of portfolio expansion, technological enhancement, and market share growth.

Major companies operating in the infectious disease diagnostics testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Grifols S.A., Hologic Inc., PerkinElmer Inc., bioMérieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin SpA (Luminex), Myriad Genetics Inc., Seegene Inc., Ortho Clinical Diagnostics Inc., OraSure Technologies Inc., Meridian Bioscience Inc., Trinity Biotech PLC, Biodesix Inc., Helix OpCo LLC, Inovio Pharmaceuticals Inc.

North America was the largest region in the infectious disease diagnostics testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease diagnostics testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the infectious disease diagnostics testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Infectious disease diagnostics testing involves identifying the presence of pathogens, such as bacteria, viruses, fungi, or parasites, in a patient's body. These tests are critical for diagnosing infectious diseases and making appropriate treatment decisions. They play a crucial role in controlling the spread of infectious diseases, guiding treatment choices, and monitoring outbreaks.

The main types of infectious disease diagnostics testing are molecular diagnostic tests and point-of-care tests (POCT) for infectious diseases. Molecular diagnostic testing refers to laboratory techniques that detect and analyze genetic material (DNA or RNA) to diagnose diseases, identify pathogens, and predict treatment responses. These tests find applications in areas such as respiratory infections, human immunodeficiency virus (HIV), healthcare-associated infections (HAIS), sexual health, tropical diseases, and liver diseases. They are utilized by various end-users including diagnostic laboratories, hospitals and clinics, academic research institutes, and other healthcare providers.

The infectious disease diagnostics testing market research report is one of a series of new reports that provides infectious disease diagnostics testing market statistics, including infectious disease diagnostics testing industry global market size, regional shares, competitors with an infectious disease diagnostics testing market share, detailed infectious disease diagnostics testing market segments, market trends, and opportunities, and any further data you may need to thrive in the infectious disease diagnostics testing industry. This infectious disease diagnostics testing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The infectious disease diagnostics testing market consists of revenues earned by entities by providing services such as laboratory testing, point-of-care testing, molecular diagnostics, immunoassays, and rapid diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The infectious disease diagnostics testing market also includes sales of diagnostic kits, reagents, instruments, and software used for detecting and identifying infectious agents in patients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.